Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
June 22, 2026
In the News
Aaron Maguregui Authors Article on Building Scalable, Secure AI Strategies
Foley & Lardner LLP partner Aaron Maguregui authored the HealthTech article, “A Digital Health CEO’s Guide to Fast, Secure Scaling of AI,” offering guidance to digital health leaders on artificial intelligence scaling.
June 5, 2026
In the News
Jeffrey Blease Featured Across the Media for Litigation Department Chair Appointment
Foley & Lardner LLP partner Jeffrey Blease is featured across legal media for his recent appointment as chair of the firm's national litigation department.
June 5, 2026
In the News
David Rosen Discusses SCOTUS Ruling on Generic Drug Labeling
Foley & Lardner LLP partner David Rosen is quoted across the media for his analysis of the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.